Mirabegron 99% powd...

Mirabegron 99% powder

Mirabegron 99% powder

Min.Order / FOB Price:Get Latest Price

1 Kilogram

Negotiable

  • Min.Order :1 Kilogram
  • Purity: 99% by HPLC
  • Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Mirabegron Mirabegron 99% 223673-61-8

Quick Details

  • Appearance:Solid powder
  • Application:Applied in dietary supplements,pharmaceutical or cosmeticeuticals
  • PackAge:aluminum foil bag,carton drum
  • ProductionCapacity:100|Kilogram|Day
  • Storage:Sealed,light and oxygen resistant
  • Transportation:by sea or air

Superiority:

Specifications
CAS No.:
223673-61-8
Other Names:
Mirabegron
MF:
C21H24N4O2S
EINECS No.:
NA
Place of Origin:
Shaanxi, China (Mainland)
Type:
Pharmaceutical Intermediates, Other
Purity:
98.5%min
Brand Name:
KONO
Model Number:
BCV-213
Application:
Pharm Intermediates
Appearance:
White Powder, White powder
Odor:
Characteristic
Water content:
≤0.3%
Packing:
Tin
Certificate:
COA,GMP...
Technical support:
Available
Supplier:
KONO
Package:
Customers Requirements/TIN

 

Details:

Introduction

CAS NO.: 223673-61-8

MF: C21H24N4O2S

MW: 396.50

Density: 1.313

storage temp.: -20°C Freezer

Refractive index: 1.68

Appearance: White to off-white powder

Purity: More than 99.0%

Usage: Potent bladder relaxant and reagent for diabetes remedy.

Function

Myrbetriq 3 is a beta - adrenergic agonist suitable for urge incontinence, urgency, and urinary frequency symptom of overactive bladder ( OAB ) treatment.

(1) the recommended starting dose is 25 mg 1 time per day, with or without food. 

(2) 25 mg is effective within 8 weeks. Based on individual efficacy and tolerability, dose can be increased to 50 mg 1 time per day.

(3) complete with water to swallow, don't chew, split or crushed. 

(4) patients with severe renal impairment or in patients with moderate hepatic impairment, the maximum dose is 25 mg 1 time per day.

(5) have end-stage renal disease (ESRD) patients or in patients with severe hepatic impairment. Not recommended for use

Application

Use in special populations

(1) the pregnancy only if the benefit to the mother outweighs the potential risks to the fetus is only used when. 

(2) nursing mothers: Myrbetriq is expected to be excreted in human milk and nursing mothers is not recommended. 

(3) children: has not been established in children with Myrbetriq safety and effectiveness. 

(4) elderly: proposal on recommends no dose adjustment in elderly patients.

Specification

Item

Specification

Result

Appearance

White crystalline powder

Complies

Related substance (HPLC)

Total impurity ≤0.5%

Max single impurity ≤0.1%

0.2%

0.06%

Odor

Characteristic

Complies

Assay

99%

99.8%

Sieve analysis

100% pass 80 mesh

Complies

Loss on Drying

Residue on Ignition

≤1.0%

≤1.0%

0.12%

0.09%

Heavy Metal

<10ppm

Complies

As

<0.1ppm

0.05ppm

Pb

<0.1ppm

0.05ppm

Cd

<0.1ppm

0.05ppm

Residual Solvents

<100ppm

Complies

Residual Pesticide

Negative

Complies

Microbiology

 

 

Total Plate Count

<1000cfu/g

Complies

Yeast & Mold

<100cfu/g

Complies

E.Coli

Negative

Complies

Salmonella

Negative

Complies

 

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View